Literature DB >> 12241118

Olfactory neuroblastomas: survival rate and prognostic factor.

Sung-Kyun Hwang1, Sun-Ha Paek, Dong Gyu Kim, Yoon-Kyung Jeon, Je G Chi, Hee-Won Jung.   

Abstract

Olfactory neuroblastomas are known to be rare and clinically malignant tumors. The authors analyzed the clinical features, long-term treatment outcomes, and prognostic factors related to 21 cases of olfactory neuroblastomas, treated between January 1979 and October 2000, retrospectively reviewed with medical records and radiologic findings. The mean follow-up period was 28.7 months (range 4-178). The extent of tumor was classified according to the UCLA staging system. Statistical analysis for survival was done using the Kaplan-Meier method and the log-rank test. The mean age was 27 years (13-62), the peak incidence occurred in the second decade (8/21, 38%), and the male to female ratio was 13:8. According to the UCLA staging system, there were 3 cases of T1, 5 of T2, 6 of T3, and 7 of T4. The 5-year survival rate was 21.3% and the average survival time was 28.9 months. The group (n = 14) undergoing radical surgical resection as the primary modality, registered a higher survival rate than the radiation and chemotherapy group (n = 7), with 2-year survival rates being 76.2% vs. 14.3%, respectively (p = 0.0274). The early stage (T1, T2) groups exhibited a better survival rate than the advanced (T3, T4) groups with 5-year survival rates being 38.1% vs. 9.1%, respectively (p = 0.0336). The mean recurrence free time was 7.8 months (range 1-25). From these findings we could conclude that tumor detection in the early stage, radical surgical resection as the primary treatment modality, and regular follow-up with radiologic evaluation for recurrence or metastasis, represent important factors for an improved outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12241118     DOI: 10.1023/a:1019937503469

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Craniofacial resection for tumors of the nasal cavity and paranasal sinuses--a 17-year experience.

Authors:  V J Lund; D J Howard; W I Wei; A D Cheesman
Journal:  Head Neck       Date:  1998-03       Impact factor: 3.147

2.  Extended anterior craniofacial resection for intracranial extension of malignant tumors.

Authors:  M H Bilsky; D H Kraus; E W Strong; L B Harrison; P H Gutin; J P Shah
Journal:  Am J Surg       Date:  1997-11       Impact factor: 2.565

3.  Esthesioneuroblastoma. Long-term outcome and patterns of failure--the University of Virginia experience.

Authors:  B V Eden; R F Debo; J M Larner; M D Kelly; P A Levine; F M Stewart; R W Cantrell; W C Constable
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

4.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

5.  Esthesioneuroblastoma and sinonasal undifferentiated carcinoma: impact of histological grading and clinical staging on survival and prognosis.

Authors:  R C Miyamoto; L L Gleich; P W Biddinger; J L Gluckman
Journal:  Laryngoscope       Date:  2000-08       Impact factor: 3.325

6.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

Review 7.  Transorbital approaches to the cranial base.

Authors:  J Bumpous; I P Janecka
Journal:  Clin Plast Surg       Date:  1995-07       Impact factor: 2.017

8.  Olfactory neuroblastoma.

Authors:  T A O'Connor; P McLean; G J Juillard; R G Parker
Journal:  Cancer       Date:  1989-06-15       Impact factor: 6.860

9.  The diagnosis and surgical management of olfactory neuroblastoma: the role of craniofacial resection.

Authors:  P Chapman; R L Carter; P Clifford
Journal:  J Laryngol Otol       Date:  1981-08       Impact factor: 1.469

10.  Craniofacial resection. An analysis of 73 cases.

Authors:  P J Catalano; C S Hecht; H F Biller; W Lawson; K D Post; V Sachdev; C Sen; M L Urken
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1994-11
View more
  18 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

2.  Esthesioneuroblastoma methods of intracranial extension: CT and MR imaging findings.

Authors:  Tian Yu; Yi-Kai Xu; Long Li; Fei-Ge Jia; Gang Duan; Yuan-Kui Wu; Hua-Yu Li; Rui-Meng Yang; Jie Feng; Xiang-Hua Ye; Ying-Wei Qiu
Journal:  Neuroradiology       Date:  2009-08-11       Impact factor: 2.804

3.  Olfactory neuroblastoma: a single-center experience.

Authors:  Marton König; Terje Osnes; Peter Jebsen; Jan Folkvard Evensen; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2017-05-25       Impact factor: 3.042

4.  The developing management of esthesioneuroblastoma: a single institution experience.

Authors:  Leif Bäck; Minna Oinas; Petra Pietarinen-Runtti; Kauko Saarilahti; Jyrki Vuola; Riste Saat; Juha Öhman; Caj Haglund; Mika Niemelä; Ilmo Leivo; Jaana Hagström; Antti A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-03-15       Impact factor: 2.503

5.  Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives.

Authors:  Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-01

Review 6.  Radiotherapy alone for local tumour control in esthesioneuroblastoma.

Authors:  G Benfari; M Fusconi; A Ciofalo; A Gallo; G Altissimi; T Celani; M De Vincentiis
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-12       Impact factor: 2.124

7.  Esthesioneuroblastoma: an update on the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy.

Authors:  Marc W Herr; Rosh K V Sethi; Joshua C Meier; Kyle J Chambers; Aaron Remenschneider; Annie Chan; William T Curry; Fred G Barker; Daniel G Deschler; Derrick T Lin
Journal:  J Neurol Surg B Skull Base       Date:  2013-09-20

8.  Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.

Authors:  Jamie J Van Gompel; Caterina Giannini; Kerry D Olsen; Eric Moore; Manolo Piccirilli; Robert L Foote; Jan C Buckner; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2012-10

9.  Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy.

Authors:  Anthony C Nichols; Annie W Chan; William T Curry; Fred G Barker; Daniel G Deschler; Derrick T Lin
Journal:  Skull Base       Date:  2008-09

10.  Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.

Authors:  Suash Sharma; Mehar C Sharma; Maribeth H Johnson; Mimi Lou; Alok Thakar; Chitra Sarkar
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.